Diabetes in COVID‐19 pandemic‐prevalence, patient characteristics and adverse outcomes-Reference-Cited by-同舟云学术

Diabetes in COVID‐19 pandemic‐prevalence, patient characteristics and adverse outcomes

Published:2021-03-14 Issue:7 Volume:75 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Abdelhafiz Ahmed H.¹^ORCID,Emmerton Demelza¹,Sinclair Alan J.²³

Affiliation:

1. Department of Geriatric Medicine Rotherham General Hospital Rotherham UK

2. Foundation for Diabetes Research in Older People Diabetes Frail Ltd, Droitwich Spa UK

3. Kings College London UK

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.14112

Reference70 articles.

1. The continuing 2019‐nCoV epidemic threat of novel coronaviruses to global health ‐ The latest, , et al. novel coronavirus outbreak in Wuhan, China;Hui DS;Int J Infect Dis,2019

2. Mortality from infectious diseases in diabetes

3. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

4. Prevalence and impact of diabetes among people infected with SARS-CoV-2

5. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications of telemedicine services using a regional telemedicine platform for cancer treatment: a cross-sectional study;BMC Cancer;2024-07-07

2. Impact of Pre-existing Type 2 Diabetes Mellitus and Cardiovascular Disease on Healthcare Resource Utilization and Costs in Patients With COVID-19;Journal of Health Economics and Outcomes Research;2024-04-19

3. Risk of COVID-19 among patients with respiratory illnesses and comorbidities at Eastern Province of Sri Lanka: A retrospective study;International Journal of Nutrition, Pharmacology, Neurological Diseases;2024-01

4. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum;Alimentary Pharmacology & Therapeutics;2023-10-25

5. COVID-19 and diabetes;Probacja;2023-09-30